New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe

Pirona, Alessandro; Ai-hua, BO; Hedrich, Dagmar; Ferri, Marica; Gelder, Nadine van; Giraudon, Isabelle; Montanari, Linda; Simon, Roland; Mounteney, Jane

doi:10.1016/j.drugpo.2016.10.004

Cited by 46 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A significant amount of research is needed to fully understand both the short and long term effects of these rapidly growing NPS in Taiwan [12], an extremely small number of cases of synthetic cathinone use identified in medical system, accounting for only 0.2% of all illegal drug cases in 2017 [13]. The marked discrepancy from these two reporting systems could be attributed to either lack of forensic capacity to identify these substances or the unawareness of clinical features of NPS by most health professionals [14,15].…”

Section: Introductionmentioning

confidence: 99%

Psychiatric Profiles and Clinical Manifestations of Cathinone Users: Case Series of Analytically Confirmed Cathinone Use in Taiwan

Chen¹

2019

AAD

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Psychiatric Profiles and Clinical Manifestations of Cathinone Users: Case Series of Analytically Confirmed Cathinone Use in Taiwan

Chen¹

2019

AAD

View full text Add to dashboard Cite

“…The percentage of those accessing treatment services for an NPS-related problem in England is currently low (Public Health England 2014b). These low levels of engagement are mirrored in Europe where NPS users in treatment represent less than one percent of all treatment demands (Pirona et al 2017). As a consequence of the small proportion of NPS users engaging with treatment services, some have warned that it is key that services do not become '… too fixated on NPS but instead focus on safer decisionmaking around substances as a whole' (Blackman & Bradley 2017:75).…”

Section: Existing Nps Service Engagementmentioning

confidence: 99%

“…Historically drug treatment services have specialised in addressing the needs of opioidusing clients -this user group still represent the largest and most problematic drug using population entering specialist treatment (40 per cent) -resulting in NPS users viewing drug treatment services as 'not for them' and unable to meet their needs (Local Government Association 2015). As Pirona et al (2017) have recently noted, this perceived gap in service provision risks leaving vulnerable populations neglected and their needs unaddressed. Consequently, Bowden-Jones et al (2014:4) call for treatment services to 'widen the front door', making the needs of NPS users their 'core business' and placing NPS on an equal footing with opiate and alcohol service user needs.…”

Section: Existing Nps Service Engagementmentioning

confidence: 99%

New psychoactive substances: new service provider challenges

Ralphs

Gray

2017

Drugs: Education, Prevention and Policy

View full text Add to dashboard Cite

This paper presents findings from a six-month study of New Psychoactive Substance (NPS) use in Manchester, UK. Drawing on interviews with 53 NPS users and 31 stakeholders, the paper documents a notable shift in the drug using landscape. It highlights how the homeless community-traditionally associated with alcohol dependency and problematic intravenous heroin and/or crack cocaine use-are now switching to smoking synthetic cannabinoid receptor agonists, while men who have sex with men (MSM) and engage in chemsex-who have traditionally been strongly associated with the recreational use of ecstasy and other stimulants-are now developing problematic intravenous drug using habits. The paper goes on to discuss the implications of this shift for existing models of treatment service delivery. In particular, it outlines the necessity for treatment services to develop innovative engagement strategies, alongside clearer referral pathways and improved service integration.

show abstract

“…In recent years, new psychoactive substances (NPS) have become an increasingly serious social problem worldwide. [1][2][3][4][5][6] NPS are defined as unknown substances and are typically produced by modifying chemical structures of known substances to circumvent legal control. Because of these chemical structure changes, NPS cannot be detected using existing drug detection tests.…”

Section: Introductionmentioning

confidence: 99%

Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction

Funada

Matsumoto

Tanibuchi

et al. 2019

Neuropsychopharm Rep

View full text Add to dashboard Cite

Aims The use of new psychoactive substances (NPS) has become increasingly widespread over the last decade, in Japan and internationally. NPS are associated with a range of increasingly serious clinical, public, and social issues. Political measures to ameliorate the effects of NPS in Japan have focused on tightening regulation rather than establishing treatment methods. The current study sought to compare the neuropsychiatric symptoms of patients with NPS‐related disorders across several years. We examined patients who attended specialized hospitals for treating addiction, to elucidate the impacts of legal measures to control NPS. Methods Subjects (n = 864) were patients with NPS‐related disorders who received medical treatment at eight specialized hospitals for treating addiction in Japan between April 2012 and March 2015. Clinical information was collected retrospectively from medical records. Results Among psychiatric symptoms, the ratio of hallucinations/delusions decreased over time across 3 years of study (first year vs second year vs third year: 40.1% vs 30.9% vs 31.7%, P = 0.037). Among neurological symptoms, the ratio of coma/syncope increased over the 3‐year period (7.8% vs 11.0% vs 17.0%, P = 0.002), as did the ratio of convulsions (2.8% vs 4.3% vs 9.7%, P = 0.001). Conclusion The symptoms associated with NPS were primarily psychiatric in the first year, while the prevalence of neurological symptoms increased each year. The risk of death and the severity of symptoms were greater in the third year compared with the first year, as regulation of NPS increased.

show abstract

New psychoactive substances: Current health-related practices and challenges in responding to use and harms in Europe

Cited by 46 publications

References 19 publications

Psychiatric Profiles and Clinical Manifestations of Cathinone Users: Case Series of Analytically Confirmed Cathinone Use in Taiwan

Psychiatric Profiles and Clinical Manifestations of Cathinone Users: Case Series of Analytically Confirmed Cathinone Use in Taiwan

New psychoactive substances: new service provider challenges

Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction

Contact Info

Product

Resources

About